drugset / Trial / NCT00075569

SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

NCT00075569

Non-randomizedParallel-groupOpen-labelPrevention

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer or to treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia. PURPOSE: This phase II trial is studying how well SGN-00101 immunotherapy works in preventing cervical cancer in patients with grade III cervical intraepithelial neoplasia.

Timeline

Start
2004-03
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator VERPASEP CALTESPEN Vaccine 500 ug Subcutaneous